Abstract
A Phase II study of thioTEPA was performed by the Children's Cancer Group. ThioTEPA was administered intravenously every three weeks, at a dose of 65 mg/m2. Pediatric patients with recurrent sarcomas were targeted, but patients with other tumor diagnoses were also eligible. Toxicity was primarily hematopoietic, with thrombocytopenia being predominant. ThioTEPA did not demonstrate significant activity in the target tumor groups evaluated.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
-
Multicenter Study
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adolescent
-
Antineoplastic Agents, Alkylating / therapeutic use*
-
Bone Neoplasms / drug therapy
-
Child
-
Humans
-
Neoplasms / drug therapy*
-
Neuroectodermal Tumors, Primitive, Peripheral / drug therapy
-
Osteosarcoma / drug therapy
-
Rhabdomyosarcoma / drug therapy
-
Sarcoma / drug therapy
-
Sarcoma, Ewing / drug therapy
-
Thiotepa / therapeutic use*
Substances
-
Antineoplastic Agents, Alkylating
-
Thiotepa